State coverage
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
Ohio writes its answer into the administrative code rather than leaving it to a drug list, and that distinction is the whole story here. Most states exclude weight-loss drugs by leaving them off a formulary, which means there's usually a prior authorization form to argue with. Ohio's rule names obesity drugs as non-covered and then, two paragraphs later, says the non-covered categories are not eligible for prior authorization at all. There is no exception to request.
That makes what happened in April 2026 worth reading closely. Ohio added Wegovy to its statewide drug list — under a class heading that says out loud what it is doing: GLP-1 agonists for non-obesity indications. There are two ways in, cardiovascular disease and liver disease, and the list states that Wegovy will not be authorized for patients with type 1 or type 2 diabetes, who are routed to a different class. Weight loss appears in those criteria only as a thing your prescriber has to document to keep the authorization, never as a reason to start.
We searched the April 1, 2026 list for each product by name. Wegovy appears five times, all inside that one class. Zepbound, Saxenda, Imcivree, Contrave, Qsymia, phentermine and orlistat return no matches anywhere in it. We ran the same search against Ohio's October 1, 2025 list as a control: Wegovy returns nothing there and the non-obesity class does not exist, so the April listing is a real change rather than an artifact of how we read the file. What a list does not mention is not the same as a coverage decision, and the exclusion above is the document that decides.
Two limits on this page. The April 1, 2026 list is the newest we could open — the pharmacy benefit manager's own document library answered with a login page rather than a file on August 31, 2026, and the state's pharmacy and therapeutics committee page renders its minutes with scripts we could not read, so a newer list may exist that we have not seen. And the appeal windows below come from Ohio's managed care rule and are written for managed care members. Ohio's fee-for-service hearing deadline sits in a statute we did not reach, so we are not printing one.
Ohio's pharmacy rule names obesity drugs as non-covered, in a list: "Drugs that fall into one of the following categories are non-covered by the Ohio medicaid pharmacy program: (1) Drugs for the treatment of obesity." The same rule then closes the usual escape hatch. Under prior authorization it says that "noncovered drugs listed in paragraphs (B)(1) to (B)(5) of this rule and APIs and excipients not on the list described in paragraph (A)(3) of this rule are not eligible for prior authorization." So for a weight-loss indication there is no criteria document to satisfy and no exception to file.
Ohio Administrative Code, Rule 5160-9-03, Ohio Laws and Administrative Rules, effective February 2024 · source · read August 2026
Wegovy is on Ohio's statewide list as of April 1, 2026, under the class heading "GLP-1 AGONISTS FOR NON-OBESITY INDICATIONS," with authorizations running 180 days. There are two approvable diagnoses. One is major adverse cardiovascular events, requiring "Age ≥18 years" and "BMI ≥27 kg/m 2" plus documented prior myocardial infarction, prior stroke or symptomatic peripheral artery disease. The other is noncirrhotic MASH with stage F2 or F3 liver fibrosis. The list adds that "WEGOVY will not be authorized for patients with type 1 or type 2 diabetes."
Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective April 2026 · source · read August 2026
Weight loss is a monitoring test on that authorization, not a way in. To keep Wegovy going, the criteria require that "Documentation (chart notes) must be submitted to show weight loss from baseline greater than or equal to 5%." You have to lose weight to stay on it, and you cannot get on it for losing weight. Both of those come from the same document.
Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective April 2026 · source · read August 2026
Ohio's October 1, 2025 list is our control for the paragraph above, and it is worth citing on its own. Searching it for Wegovy returns nothing, and the non-obesity GLP-1 class does not appear in it at all, while the same file carries the same diabetes GLP-1 roster the April list carries. The search works on the older document, so Wegovy's arrival in April 2026 is a change Ohio made, not a difference in how we read the two files.
Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective October 2025 · source · read August 2026
Shopping between Ohio Medicaid plans will not get you a different answer, because they all use the same drug list and the same pharmacy administrator. State law directs that "the medicaid director, through a procurement process, shall select a third-party administrator to serve as the single pharmacy benefit manager used by medicaid managed care organizations under the care management system." The list itself is titled for "Medicaid Fee-for-Service and Managed Care Plans."
Ohio Revised Code §5167.24, Ohio Laws and Administrative Rules, effective September 2025 · source · read August 2026
If an Ohio managed care plan or the state pharmacy benefit manager denies you, there are two clocks and you have to run them in order. First the plan's own appeal: a member or representative "may file an appeal orally or in writing within sixty calendar days from the date that the NOA was issued." You cannot skip it — "members may request a state hearing only after exhausting the MCO or SPBM's appeal process." Then the hearing: you "may request a state hearing within ninety calendar days from the date of an adverse appeal resolution." This rule is written for managed care members; we did not reach Ohio's fee-for-service hearing deadline, so we are not stating one.
Ohio Administrative Code, Rule 5160-26-08.4, Ohio Laws and Administrative Rules, effective January 2023 · source · read August 2026
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.